Thrombocytosis: Clinical Trials

73 trials for Thrombocytosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

44 completed, 11 recruiting, 7 terminated, 5 active not recruiting. 73 Phase 1, 25 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 173Completed 44, Recruiting 11, Terminated 7, Active not recruiting 5, Withdrawn 4, Unknown 2
Phase 225Completed 17, Withdrawn 3, Recruiting 2, Active not recruiting 1, Terminated 1, Unknown 1

Follow Thrombocytosis: new trials by email Literature Review of Thrombocytosis trials Research Report on Thrombocytosis

Trials (filtered) newest first · largest first

All 73 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
DMR-001, Ruxolitinib - Myeloproliferative Neoplasms (MPNs)
Phase 1RecruitingDamora Therapeutics2502026-09-012026-10-27
Therapeutic RSK1 Targeting in Myeloid Malignancies
PMD-026 - Myeloid Malignancy
Phase 1RecruitingWashington University School of Medicine302026-05-202026-10-21
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
INCA036978, Standard disease-directed therapy - Myeloproliferative Neoplasms
Phase 1RecruitingIncyte Corporation2182026-05-112026-11-13
Safety and Tolerability of ZE74-0282 in Healthy Volunteers
ZE74-0282-0001 or placebo - Healthy Volunteers
Phase 1RecruitingEilean Therapeutics AU Pty Ltd642026-04-162026-07-28
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
INCA035784 - Myeloproliferative Neoplasms
Phase 1RecruitingIncyte Corporation1202025-10-012026-08-06
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis
JBI-802 - Essential Thrombocythemia (ET), Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)
Phase 1 / Phase 2RecruitingJubilant Therapeutics Inc.302024-10-212026-06-03
A Study of GLB-001 in Patients With Myeloid Malignancies
GLB-001 - Polycythemia Vera, Essential Thrombocythemia
Phase 1RecruitingHangzhou GluBio Pharmaceutical Co., Ltd.1082024-05-242025-08-19
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Talazoparib, pacritinib - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Phase 1RecruitingFox Chase Cancer Center242024-04-052024-05-03
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
INCA033989, Ruxolitinib - Myeloproliferative Neoplasms
Phase 1RecruitingIncyte Corporation2902023-12-042026-04-17
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
INCA033989, Ruxolitinib - Myeloproliferative Neoplasms
Phase 1Active not recruitingIncyte Corporation1602023-09-252026-08-10
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
Peptide-based vaccine, Poly ICLC - Myelofibrosis, Essential Thrombocythemia
Phase 1Active not recruitingMarina Kremyanskaya72023-04-042026-09-28
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
CK0804 - Myelofibrosis
Phase 1RecruitingCellenkos, Inc.242022-12-272026-10-21
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
N-Acetylcysteine - Myeloproliferative Neoplasm, MPN
Phase 1 / Phase 2RecruitingUniversity of California, Irvine272022-01-032026-03-10
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
INCB057643, Ruxolitinib - Myelofibrosis, Myelodysplastic Syndrome
Phase 1Active not recruitingIncyte Corporation1402021-02-232026-04-01
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
TAS1553 - Acute Myeloid Leukemia, Myeloproliferative Neoplasm
Phase 1TerminatedAstex Pharmaceuticals, Inc.202020-12-212024-08-02
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
APG-1252, Ruxolitinib - Myelofibrosis
Phase 1 / Phase 2WithdrawnAscentage Pharma Group Inc.2020-12-152022-07-12
Study of Select Combinations in Adults With Myelofibrosis
MBG453, NIS793, Spartalizumab - Primary Myelofibrosis, Myelofibrosis
Phase 1WithdrawnNovartis Pharmaceuticals2020-11-302021-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8
Phase 1TerminatedOHSU Knight Cancer Institute22020-04-012024-03-04
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
Navitoclax, Ruxolitinib, Celecoxib - Myeloproliferative Neoplasm
Phase 1Active not recruitingAbbVie852019-11-082025-02-14
Dual Vaccine Trial in Myeloproliferative Neoplasms
PD-L1 peptide: PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL, Arginase1 peptide: ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL - Polycythemia Vera, Essential Thrombocythemia
Phase 1 / Phase 2CompletedInge Marie Svane92019-07-102023-07-13

Showing 20 of 73. Sign in to see all of them.

Narrower conditions

Thrombocythemia, Essential (68)  ·  Primary Myelofibrosis (66)  ·  Myeloproliferative Disorders (58)  ·  Polycythemia Vera (57)  ·  Leukemia, Myeloid, Acute (40)  ·  Leukemia, Myelomonocytic, Chronic (36)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (34)  ·  Myelodysplastic Syndromes (33)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (30)  ·  Leukemia (28)  ·  Burkitt Lymphoma (26)  ·  Lymphoma, Follicular (26)  ·  Lymphoma, Mantle-Cell (26)  ·  Lymphoma, Non-Hodgkin (26)  ·  Multiple Myeloma (26)

Broader conditions

Hemic and Lymphatic Diseases (73)  ·  Blood Platelet Disorders (72)  ·  Bone Marrow Diseases (68)  ·  Hematologic Diseases (68)  ·  Hemorrhagic Disorders (68)  ·  Blood Coagulation Disorders (67)  ·  Neoplasms (61)  ·  Neoplasms by Site (61)  ·  Hematologic Neoplasms (58)  ·  Bone Marrow Neoplasms (57)  ·  Disease Attributes (45)  ·  Leukemia, Myeloid (45)  ·  Neoplasms by Histologic Type (45)  ·  Pathologic Processes (45)

Interventions

ruxolitinib (12)  ·  Peripheral Blood Stem Cell Transplantation (9)  ·  Cyclophosphamide (6)  ·  Cyclosporine (6)  ·  fludarabine phosphate (5)  ·  Antilymphocyte Serum (4)  ·  Busulfan (4)  ·  Carboplatin (4)  ·  Decitabine (4)  ·  Filgrastim (4)  ·  Methotrexate (4)  ·  Cytarabine (3)  ·  Etoposide (3)  ·  Methylprednisolone (3)  ·  Tacrolimus (3)

Sponsors

National Cancer Institute (NCI) (7)  ·  Incyte Corporation (6)  ·  Fred Hutchinson Cancer Center (4)  ·  Eli Lilly and Company (3)  ·  California Cancer Consortium (2)  ·  Inge Marie Svane (2)  ·  M.D. Anderson Cancer Center (2)  ·  Mayo Clinic (2)  ·  Northwestern University (2)  ·  Novartis Pharmaceuticals (2)  ·  OHSU Knight Cancer Institute (2)  ·  AbbVie (1)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Asan Medical Center (1)  ·  Ascentage Pharma Group Inc. (1)

Countries

United States (61)  ·  Australia (8)  ·  Italy (8)  ·  Germany (7)  ·  United Kingdom (7)  ·  Canada (6)  ·  France (6)  ·  Belgium (5)  ·  Spain (5)  ·  Denmark (4)  ·  Japan (4)  ·  China (2)  ·  Netherlands (2)  ·  Poland (2)  ·  South Korea (2)

Top investigators

Ayalew Tefferi, MD (2)  ·  Jacob H Grauslund, MD (2)  ·  Jorge Cortes, MD (2)  ·  Richard K. Burt, MD (2)  ·  Ronald Hoffman, MD (2)  ·  Todd M. Zimmerman, MD (2)  ·  Alex Shalaurov, MD, PhD (1)  ·  Amy W Zhou, M.D. (1)  ·  Andrew Roberts, M.D. (1)  ·  Angela Fleischman, MD, PhD (1)  ·  Ann E. Woolfrey, MD (1)

Results publications

PMID 15570084, PMID 20843246, PMID 22259028, PMID 22718840, PMID 24474568, PMID 25563429, PMID 25762180, PMID 26210442, PMID 26853648, PMID 27479177, PMID 28934680, PMID 29544547, PMID 30562587, PMID 31167802, PMID 32634234, PMID 33718228, PMID 36881782, PMID 36911725, PMID 37422688, PMID 37530627, PMID 38259250, PMID 39863139

NIH funding

2018 (2), P30CA015083 (2), U01CA062491 (2), 2019 (1), 2023 (1), P01CA018029 (1), P01CA108671 (1), P30CA006973 (1), P30CA016058 (1), P30CA016086 (1), P30CA016087 (1), P30CA023074 (1), P30CA033572 (1), P30CA036727 (1), P30CA072720 (1)